Literature DB >> 11272165

beta-cell genes and diabetes: quantitative and qualitative differences in the pathophysiology of hepatic nuclear factor-1alpha and glucokinase mutations.

E R Pearson1, G Velho, P Clark, A Stride, M Shepherd, T M Frayling, M P Bulman, S Ellard, P Froguel, A T Hattersley.   

Abstract

Mutations in the beta-cell genes encoding the glycolytic enzyme glucokinase (GCK) and the transcription factor hepatocyte nuclear factor (HNF)-1alpha are the most common causes of maturity-onset diabetes of the young (MODY). Studying patients with mutations in these genes gives insights into the functions of these two critical beta-cell genes in humans. We studied 178 U.K. and French MODY family members, including 45 GCK mutation carriers and 40 HNF-1alpha mutation carriers. Homeostasis model assessment of fasting insulin and glucose showed reduced beta-cell function in both GCK (48% controls, P<0.0001) and HNF-1alpha (42% controls, P<0.0001). Insulin sensitivity was similar to that of control subjects in the GCK subjects (93% controls, P = 0.78) but increased in the HNF-1alpha subjects (134.5% controls, P = 0.005). The GCK patients showed a similar phenotype between and within families with mild lifelong fasting hyperglycemia (fasting plasma glucose [FPG] 5.5-9.2 mmol/l, interquartile [IQ] range 6.6-7.4), which declined slightly with age (0.017 mmol/l per year) and rarely required pharmacological treatment (17% oral hypoglycemic agents, 4% insulin). HNF-1alpha patients showed far greater variation in fasting glucose both between and within families (FPG 4.1-18.5 mmol/l, IQ range 5.45-10.4), with a marked deterioration with age (0.06 mmol/l per year), and 59% of patients required treatment with tablets or insulin. Proinsulin-to-insulin ratios are increased in HNF-1alpha subjects (29.5%) but not in GCK (18.5%) subjects. In an oral glucose tolerance test, the 0- to 120-min glucose increment was small in GCK patients (2.4+/-1.8 mmol/l) but large in HNF-1alpha patients (8.5+/-3.0 mmol/l, P< 0.0001). This comparison shows that the clear clinical differences in these two genetic subgroups of diabetes reflect the quantitative and qualitative differences in beta-cell dysfunction. The defect in GCK is a stable defect of glucose sensing, whereas the HNF-1alpha mutation causes a progressive defect that alters beta-cell insulin secretion directly rather than the sensing of glucose.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11272165     DOI: 10.2337/diabetes.50.2007.s101

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  30 in total

Review 1.  Molecular etiologies of MODY and other early-onset forms of diabetes.

Authors:  David Q Shih; Markus Stoffel
Journal:  Curr Diab Rep       Date:  2002-04       Impact factor: 4.810

Review 2.  When is it MODY? Challenges in the Interpretation of Sequence Variants in MODY Genes.

Authors:  Sara Althari; Anna L Gloyn
Journal:  Rev Diabet Stud       Date:  2016-02-10

3.  Clinical assessment of HNF1A and GCK variants and identification of a novel mutation causing MODY2.

Authors:  Ashley H Shoemaker; Jozef Zienkiewicz; Daniel J Moore
Journal:  Diabetes Res Clin Pract       Date:  2012-02-16       Impact factor: 5.602

4.  Effects of novel maturity-onset diabetes of the young (MODY)-associated mutations on glucokinase activity and protein stability.

Authors:  María Galán; Olivier Vincent; Isabel Roncero; Sharona Azriel; Pedro Boix-Pallares; Elías Delgado-Alvarez; Francisco Díaz-Cadórniga; Enrique Blázquez; María-Angeles Navas
Journal:  Biochem J       Date:  2006-01-01       Impact factor: 3.857

5.  Molecular genetics and phenotypic characteristics of MODY caused by hepatocyte nuclear factor 4alpha mutations in a large European collection.

Authors:  E R Pearson; S Pruhova; C J Tack; A Johansen; H A J Castleden; P J Lumb; A S Wierzbicki; P M Clark; J Lebl; O Pedersen; S Ellard; T Hansen; A T Hattersley
Journal:  Diabetologia       Date:  2005-04-14       Impact factor: 10.122

6.  Functional analysis of human glucokinase gene mutations causing MODY2: exploring the regulatory mechanisms of glucokinase activity.

Authors:  C M García-Herrero; M Galán; O Vincent; B Flández; M Gargallo; E Delgado-Alvarez; E Blázquez; M A Navas
Journal:  Diabetologia       Date:  2006-12-21       Impact factor: 10.122

7.  Aetiological heterogeneity of asymptomatic hyperglycaemia in children and adolescents.

Authors:  E Feigerlová; S Pruhová; L Dittertová; J Lebl; D Pinterová; K Kolostová; M Cerná; O Pedersen; T Hansen
Journal:  Eur J Pediatr       Date:  2006-04-07       Impact factor: 3.183

8.  Alx3-deficient mice exhibit decreased insulin in beta cells, altered glucose homeostasis and increased apoptosis in pancreatic islets.

Authors:  M Mirasierra; A Fernández-Pérez; N Díaz-Prieto; M Vallejo
Journal:  Diabetologia       Date:  2010-11-21       Impact factor: 10.122

9.  Beta cell function and insulin sensitivity in obese youth with maturity onset diabetes of youth mutations vs type 2 diabetes in TODAY: Longitudinal observations and glycemic failure.

Authors:  Silva Arslanian; Laure El Ghormli; Morey H Haymond; Christine L Chan; Steven D Chernausek; Rachelle G Gandica; Rose Gubitosi-Klug; Lynne L Levitsky; Maggie Siska; Steven M Willi
Journal:  Pediatr Diabetes       Date:  2020-03-03       Impact factor: 4.866

10.  Assessing the phenotypic effects in the general population of rare variants in genes for a dominant Mendelian form of diabetes.

Authors:  Jason Flannick; Nicola L Beer; Alexander G Bick; Vineeta Agarwala; Janne Molnes; Namrata Gupta; Noël P Burtt; Jose C Florez; James B Meigs; Herman Taylor; Valeriya Lyssenko; Henrik Irgens; Ervin Fox; Frank Burslem; Stefan Johansson; M Julia Brosnan; Jeff K Trimmer; Christopher Newton-Cheh; Tiinamaija Tuomi; Anders Molven; James G Wilson; Christopher J O'Donnell; Sekar Kathiresan; Joel N Hirschhorn; Pål R Njølstad; Tim Rolph; J G Seidman; Stacey Gabriel; David R Cox; Christine E Seidman; Leif Groop; David Altshuler
Journal:  Nat Genet       Date:  2013-10-06       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.